Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis

Key Points

• Evaluate the effectiveness and safety of trametinib in pediatric patients with refractory/relapse LCH.
• Monotherapy treatment with trametinib administered to pediatric patients with refractory LCH.
• Assessment of effectiveness and safety throughout the treatment period.
• Trametinib demonstrated effectiveness in treating refractory/relapse LCH in pediatric patients.
• The treatment was found to be safe with manageable side effects.